Mink therapeutics announces promising preclinical activity of mink-215 against colorectal cancer liver metastases at aacr

New york, april 08, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced the presentation of data from mink-215, an investigational il-15 armored fibroblast activation protein (fap) targeting car-inkt cell therapy, at the american association for cancer research (aacr) meeting in san diego, ca.
INKT Ratings Summary
INKT Quant Ranking